Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
67 hedge funds and large institutions have $17.2M invested in Accelerate Diagnostics in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 16 closing their positions.
4% less capital invested
Capital invested by funds: $18M → $17.2M (-$756K)
8% less funds holding
Funds holding: 73 → 67 (-6)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
72% less call options, than puts
Call options by funds: $8K | Put options by funds: $29K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Griffin Asset Management
New York
|
+$1.01M |
| 2 |
AF
Allworth Financial
Folsom,
California
|
+$92.6K |
| 3 |
TC
Tejara Capital
London,
United Kingdom
|
+$60.1K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$35.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$30.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$876K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$437K |
| 3 |
DKCM
Davidson Kempner Capital Management
New York
|
-$173K |
| 4 |
Millennium Management
New York
|
-$95.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$72.1K |
AXDX Hedge Fund Activity: Q1 2023 in Review
67 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q1 2023, worth a combined $17.2M — down 4.2% from $18M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AXDX and 10 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 11 added.
The largest buyer was Griffin Asset Management, adding an estimated $1.01M. The largest seller was JP Morgan Chase, cutting an estimated $876K.
- 67 institutional investors held Accelerate Diagnostics (AXDX) as of Q1 2023, down from 73 in Q4 2022.
- Funds reported $17.2M of Accelerate Diagnostics stock for Q1 2023, down 4.2% quarter-over-quarter.
- 10 funds opened new Accelerate Diagnostics positions in Q1 2023 and 16 closed out, a net change of -6 holders.
- The largest Accelerate Diagnostics buyer in Q1 2023 was Griffin Asset Management, an estimated $1.01M added.
- The largest Accelerate Diagnostics seller in Q1 2023 was JP Morgan Chase, an estimated $876K sold.
Based on aggregated 13F filings for Q1 2023.